nykode therapeutics

Q2 2024 Results Presentation

August 21, 2024

Forward-looking statement

This announcement and any materials distributed in connection with this presentation may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate.

A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Today’s presenters from Nykode management

International management team with solid drug development experience

MICHAEL ENGSIG

Chief Executive Officer

AGNETE FREDRIKSEN

Chief Scientific Officer & Business Development

HARALD GURVIN

Chief Financial Officer

KLAUS EDVARDSEN

Chief Research & Development Officer

Q2 2024 Highlights

- Strategic repositioning of VB10.16 to focus the development on locally advanced cervical cancer and recurrent metastatic head and neck cancer (post-period end).
- Discontinuation of the VB-C-04 trial (post-period end).
- Announced clinical collaboration with MSD to evaluate VB10.16 in combination with KEYTRUDA® (pembrolizumab) in patients with HPV16-positive high-risk locally advanced cervical cancer.
- Decision to no longer pursue the NYK011 preclinical program to focus oncology pipeline on partnered programs and clinical assets (post-period end).
- Issuance of key patent covering Nykode's individualized neoantigen based vaccines, VB10.NEO in the US (post-period end).
- Presented data on the APC-targeted neoantigen vaccines in a mRNA format substantiating its superiority over antigen alone vaccines.
- Presented advancements in the inverse vaccine platform, highlighting the versatility and effectiveness of Nykode's APC-targeting technology in preclinical models
- Revealed plans to form a new subsidiary focused on advancing the immune tolerance platform

Broad pipeline targeting early to late-stage cancer treatment

	Asset	Indication	Rights	Preclinical	Phase 1	Phase 2	Phase 3	Upcoming Catalyst
Oncology								
Off-the-shelf	VB10.16	HPV16+ cervical cancer	nykode [1]				C-02	Publication of final data
		HPV16+ head and neck cancer	nykode [2]			C-03		Dose level recommendation (2H 2024)
		HPV16+ locally advanced cervical cancer	nykode [2]				C-05	Protocol in development. Final design in 2H
	Regeneron programs	Undisclosed	nykode REGENERON [3]					Selection of lead candidate
Individualized	VB10.NEO	Incurable locally advanced and metastatic tumors	nykode Genentech [4]			N-02		
Infectious Disease								
Regeneron programs		Undisclosed	nykode REGENERON [3]					
Autoimmune								
Internal		Undisclosed	nykode					Update in Q4

1. Wholly-owned by Nykode. Potentially registrational. Roche supplies atezolizumab; 2. Wholly-owned by Nykode. Merck (MSD) supplies pembrolizumab; 3. Collaboration with Regeneron; 4. Genentech has an exclusive license to VB10.NEO.

R&D update

Strategic repositioning of VB10.16

- Strategic repositioning of VB10.16 to focus the development on locally advanced cervical cancer and recurrent metastatic head and neck cancer.

- Discontinuation of the VB-C-04 trial.
  - C-04 initially expected to provide a fast-to-market path for VB10.16.
  - Full FDA approval of Tivdak® extended C-04 trial timelines.

Data from C-02 supports our efforts in locally advanced settings



- Supports deepening responses in combination with an CPI.
- Demonstrated **capacity to maintain clinical benefit irrespective of degree of disease control**.
- Final clinical data to be presented in a future scientific publication.

VB-C-05 locally advanced cervical cancer

- Clinical collaboration with MSD to evaluate VB10.16 in combination with KEYTRUDA® (pembrolizumab) in patients with HPV16-positive high-risk locally advanced cervical cancer
- Incorporate VB10.16 into the existing treatment regimen of pembrolizumab with chemoradiation, which has recently gained approval for this specific cancer indication

VB10.NEO Individualized cancer immunotherapy

Nykode's individualized cancer vaccine is designed to target a broad range of tumours

Vaccine design

- APC-targeted vaccine technology leverages targeting unit to enhance CD8+ response
- Induces immune response in hard-to-treat patients with low TMB

Sequencing of biopsy tissue

- Proprietary neoantigen selection algorithm optimizes predicted immune response profile
- Strong & broad antigen-specific response, with ~53% immunogenic neoepitopes per patient

Manufacture one vaccine per patient

- pDNA fast and robust manufacturing with high success rate and cost-effective manufacturing
- Rapid turnaround time from biopsy to vaccination

Clinical site

- Broad applicability across tumor types, including CPI-refractory and 'cold' tumors
- Safe and well-tolerated in combination with CPI

Key clinical results

- 2 clinical trials in more than 10 indications in recurrent / metastatic setting
- Broad and durable T cell responses in clinic, with neoantigen-specific T-cell clones sustained over 1 year
- Polyfunctional T-cell response predominated by CD8+ T-cells
- Immune responses correlate with clinical responses

*Exclusively out-licensed to Roche and Genentech (2020)

New Patent Granted for VB10.NEO

- **VB10.NEO:** Nykode's fully individualized neoantigen based vaccine.
- **U.S. Patent No. 12,059,459:** entitled, "Therapeutic Anticancer Neoepitope Vaccine."
- **Patent Expiration:** The 20-year expiration date of this patent is January 5, 2037.
- **Related Patents:** Previously granted to the company in Russia, India, and Australia.

mRNA oncology vaccine

Nykode’s APC targeting technology can leverage mRNA vaccines and presents opportunity for platform expansion

- Targeted delivery via APCs using Nykode’s technology has been shown to induce broader and stronger CD8+ immune responses vs. existing ‘antigen-alone’ approaches.
- Preclinical studies have demonstrated that Nykode’s APC-targeted vaccines delivered as mRNA improves the number of immunogenic antigens vs. ‘antigen-alone’ approaches
- New data from Q2 further substantiates this improved immunogenicity across doses and time points, shows the bias to induce CD8 T cell responses and translation into superior tumor control.
- The potential to leverage Nykode’s APC targeted approach across vectors and formulations presents a significant growth opportunity for Nykode’s broad oncology platform and broadens the partnering opportunity space

The Nykode vaccine elicits stronger T cell responses

The Nykode vaccine elicits stronger T cell responses across a range of mRNA-LNP doses

single (prime) vaccination



prime + boost vaccination



C57BL/6 n=5 per group | Vaccination (1ug) on day 0 & 21 | IFN-g fluorospot on day 7 (prime) & 28 (prime + boost)

The Nykode vaccine elicits broader T cell responses that are biased toward cytotoxic CD8+ T cells

Nykode vaccine targets more neoantigens



Induction of Cytotoxic CD8+ T Cells

prime + boost vaccination 1ug dose



The Nykode vaccine provides superior tumor control

The Nykode vaccine led to efficient tumor rejection, slowed tumor growth, and increased survival





C57BL/6 n=12 per group | 10^5 MC38 tumor cells injected on day 0 | Vaccination (2ug) on days 0, 7, 14

Autoimmunity platform update

Induction of antigen specific tolerance can be achieved by targeting disease causing epitopes to tolerogenic APCs

MECHANISM OF ACTION – TOLERANCE INDUCTION (INVERSE VACCINATION)



1 Cells encode and secrete Tol APC-targeted Vaccibody proteins together with immunosuppressive molecules/modulators to enhance tolerogenic APC function.

2 The Tol APCs present vaccine antigens in a tolerogenic milieu supported by the vaccine co-encoded suppressive molecules, and prime regulatory T cell (Treg) activation and expansion.

3 The Tregs inhibit or delete disease-specific effector T cells and inhibit effector B cells

Nykode vaccine deliver early therapeutic disease protection, in contrast to equimolar dose of antigen peptide alone



EAE MODEL – EARLY THERAPEUTIC DELIVERY





Mann-Whitney test, **p<0.01

Nykode vaccine targeting different receptors on APCs is effective as early therapeutic in EAE





EAE MODEL – EARLY THERAPEUTIC DELIVERY





Mann-Whitney test, **p<0.01, ***p<0.001.

Recent autoimmunity updates further substantiate the potential of Nykode's APC-targeted platform

- New data highlight the versatility and effectiveness of Nykode's APC-targeting technology within the broad field of immune tolerance
  - Efficacy in therapeutic setting with two different APC-targeting units
  - Improved efficacy compared to antigen alone
- As part of a step to advance these efforts, Nykode is establishing a subsidiary focusing on immune tolerance

Q2 2024
Financial Results

Income Statement

Amounts in USD '000	Q2 2024	Q2 2023	YTD 2024	YTD 2023
Revenue from contracts with customers	544	5,000	1,371	8,126
Other income	40	100	229	281
Total revenue and other income	**584**	**5,100**	**1,600**	**8,406**
Employee benefit expenses	5,763	5,143	14,585	11,800
Other operating expenses	6,040	11,354	13,269	22,222
Depreciation	568	542	1,138	1,007
Operating profit (loss)	**(11,787)**	**(11,939)**	**(27,392)**	**(26,622)**
Finance income	2,856	2,537	5,101	5,845
Finance costs	556	821	3,645	1,439
Profit (loss) before tax	**(9,487)**	**(10,223)**	**(25,936)**	**(22,216)**
Income tax expense	(2,099)	(1,012)	(3,603)	(2,643)
Profit (loss) for the period	**(7,388)**	**(9,211)**	**(22,333)**	**(19,572)**

Revenue from contracts with customers

- R&D activities under Genentech and Regeneron agreements
- $0.5m (Q2 2024) and $1.2m (H1 2024) under Genentech agreement
- $0.1m (Q2 2024) and $0.2m (H1 2024) under Regeneron agreement

Other income

- Government grants from SkatteFUNN and Research Council of Norway

Employee benefit expenses

- Increase due to growth in organization

Other operating expenses

- Reduction mainly due to finalization of enrolment under N-02 trial

Finance income/costs

- Mainly interest income and unrealized currency loss

Balance Sheet

Amounts in USD '000	30/06/2024	31/12/2023
ASSETS		
Non-current assets		
Property, plant and equipment	4,058	4,413
Right-of-use assets	5,226	6,104
Intangible assets	72	70
Other non-current receivables	30,501	31,923
Total non-current assets	**39,857**	**42,510**
Current assets		
Trade receivables	-	-
Other receivables	3,486	3,073
Cash and cash equivalents	136,534	162,602
Total current assets	**140,020**	**165,675**
TOTAL ASSETS	**179,877**	**208,185**

Cash and cash equivalents

- Strong cash position of $136.5m at June 30, 2024

Other non-current receivables

- Mainly reflects the NOK 325 million payment to the Norwegian Tax Authorities (NTA) in the fourth quarter of 2023 following the decision by the NTA on the tax treatment of upfront payments received under a license agreement entered into in 2020
- Nykode has appealed the decision to the Norwegian Tax Administration (Norw: Skatteklagenemda)
- Receivable is in NOK and USD equivalent will fluctuate with exchange rate movements

Balance Sheet - contd.

Amounts in USD '0008	31/03/2024	31/12/2023
EQUITY AND LIABILITIES		
Equity		
Share capital	367	367
Share premium	128,986	128,986
Other capital reserves	18,043	15,395
Other components of equity	(3,044)	(3,048)
Retained earnings	7,726	29,559
Total equity	**152,07**	**171,259**
Non-current liabilities		
Non-current lease liabilities	3,389	4,269
Non-current provisions	-	2
Other non-current liabilities	877	-
Deferred tax liabilities	8,444	12,047
Total non-current liabilities	**12,710**	**16,318**
Current liabilities		
Government grants	-	104
Current lease liabilities	1,397	1,457
Trade and other payables	3,417	7,064
Current provisions	2,986	3,750
Current contract liabilities	7,289	8,233
Income tax payable	-	-
Total current liabilities	**15,089**	**20,608**
Total liabilities	**27,799**	**36,926**
TOTAL EQUITY AND LIABILITIES	**179,877**	**208,185**

Equity

- Total equity of $152m as per June 30, 2024
- Equity ratio of 85%

Contract liabilities

- Payments received/due for services not rendered under the Genentech agreement
- Invoicing follows milestone payments
- Revenues recognized as services are delivered
- Contract liability of $7.3m per June 30, 2024, down from $8.2m per December 31, 2023, in line with revenues recognized

Upcoming milestones

Oncology	Q1 '24		**VB10.16 Cervical Cancer**	Updated survival data from VB-C-02 Phase 2 trial
	2H '24		**VB10.16 Head and Neck Cancer**	Recommended Phase 2 dose in PD-L1+ patients with 1st line recurrent/metastatic advanced head and neck cancer
Auto-immune	1H '24		**Autoimmunity and Allergy**	Update on Nykode's inverse vaccine technology platform
	Q4 '24		**Autoimmunity and Allergy**	Update on Nykode's inverse vaccine technology platform
Other	1H '24		**Platform**	Update on Nykode's APC targeted vaccine technology delivered by mRNA
	Q4 '24		**Platform**	Update on Nykode's APC targeted vaccine technology delivered by mRNA

Note: The news flow from the collaboration with Genentech and Regeneron is at their discretion, respectively

UNLOCKING THE FUTURE OF MEDICINE

Contact:
Alexandra Deschner
Head of Investor Relations
IR@nykode.com